-Reuters
B. Riley Securities Maintains Buy on Fortress Biotech, Lowers Price Target to $6
B. Riley Securities analyst Mayank Mamtani maintains Fortress Biotech (NASDAQ:FBIO) with a Buy and lowers the price target from $8 to $6.
Related Posts
Tudor Pickering Downgrades Occidental Petroleum to Hold
Tudor Pickering analyst Matthew Portillo downgrades Occidental Petroleum (NYSE:OXY) from Buy to Hold.
Advance Auto Parts Stock Dips Amid Slow Start To 2024 – What’s Going On?
Advance Auto Parts CEO announces reinvestment of savings into business support, as Q1 earnings beat expectations but sales decline slightly.
BioNTech Announces Strategic Partnership With U.K. Government To Provide Up To 10,000 Patients With Personalized mRNA Cancer Immunotherapies By 2030
Multi-year collaboration focuses on three strategic pillars: cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech's footprint in the UK
BioNTech aims to design and roll out randomized